A Study of NST-6179 in Subjects With Intestinal Failure-Associated Liver Disease (IFALD).
					This is a phase 2a, multicenter, randomized, double-blind, placebo-controlled study to
evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of
NST-6179 in subjects with intestinal failure-associated liver disease (IFALD) receiving
paren...
					
						
							
						
						
							
								
									
										Age: 16 years - 66+
									
								
								
									
										Gender: All
									
								
							 
						
					 
				
			
				
					Bridge to HOPE: Hypothermic Oxygenated Perfusion Versus Cold Storage Prior to Liver Transplantation
					This is a prospective, multi-center, controlled, randomized, pivotal study to evaluate the
 safety and effectiveness of the VitaSmart Liver Machine Perfusion System by comparing
 clinical outcomes in patients undergoing liver transplantation with ex-vivo liver
 prese...
					
						
							
						
						
							
								
									
										Age: 18 years - 66+
									
								
								
									
										Gender: All
									
								
							 
						
					 
				
			
				
					A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
					A 52-Week, Multi-center, Open-label, Active Treatment Extension Study to Evaluate Safety and
 Tolerability of Once Daily, Oral Administration of Resmetirom (MGL-3196)
					
						
							
						
						
							
								
									
										Age: 18 years - 66+
									
								
								
									
										Gender: All
									
								
							 
						
					 
				
			
				
					Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs
					Management of ACLF is mainly supportive. The poor outcomes lead physicians to consider
liver transplantation as an option, even if controversial. In sicker recipients, LT
results in immediate survival, but poor medium-term survival rates in some studies. The
scarcity...
					
						
							
						
						
							
								
									
										Age: 18 - 80 years
									
								
								
									
										Gender: All
									
								
							 
						
					 
				
			
				
					Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs
					Management of ACLF is mainly supportive. The poor outcomes lead physicians to consider liver transplantation as an option, even if controversial. In sicker recipients, LT results in immediate survival, but poor medium-term survival rates in some studies. The scarcity of...
					
						
							
						
						
							
								
									
										Age: 18 - 80 years
									
								
								
									
										Gender: All
									
								
							 
						
					 
				
			
				
					Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study
					This phase II trial investigates how well lisinopril may work in preventing the
progression of non-alcoholic fatty liver disease (NAFLD). NAFLD is a condition where
there is an accumulation of fatty cells in the liver. NAFLD increases a person's risk of
developing li...
					
						
							
						
						
							
								
									
										Age: 18 years - 66+
									
								
								
									
										Gender: All
									
								
							 
						
					 
				
			
				
					Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study
					This phase II trial investigates how well lisinopril may work in preventing the progression of non-alcoholic fatty liver disease (NAFLD). NAFLD is a condition where there is an accumulation of fatty cells in the liver. NAFLD increases a person's risk of developing liver...
					
						
							
						
						
							
								
									
										Age: 18 years - 66+
									
								
								
									
										Gender: All